OR WAIT null SECS
September 02, 2019
Innovation in manufacturing technologies must occur to ensure the availability of gene therapies and cell therapies.
August 02, 2019
A design strategy can ensure conflicting properties are managed appropriately for multi-API controlled-release formulations.
To help customers succeed, CDMOs have moved away from the ‘fee-for-service’ model to offer flexible, full-service partnerships.
Formulators of parenteral drugs must be cautious of specific considerations and challenges that arise during development and manufacture.
July 02, 2019
AstraZeneca has revealed that the CHMP of the European Medicines Agency has given a positive opinion to adding a self-administration option for Fasenra (benralizumab).
Several trends are driving change in oral solid‑dosage forms and giving rise to the requirement of ‘fit-for-purpose’ excipients.
Nanotechnology is enabling enhanced bioavailability, improved stability, and targeted delivery of challenging APIs.
June 02, 2019
Excipients and new processing techniques can make a real difference in the development of highly potent therapies.
Exploration of various formulation techniques is vital to provide effective delivery of poorly soluble drugs.
Discussing the advantages, limitations, and recent advances of HME with experts from AbbVie.